NCT00444314View on ClinicalTrials.gov

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

October 31, 2009

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Panzem® NCD

NCD suspension, 1500 mg TID daily for 6 week cycles

DRUG

Sunitinib Malate

Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle

Trial Locations (3)

21205

Johns Hopkins University School of Medicine, Baltimore

46202

Indiana University Cancer Center, Indianapolis

53792

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY